Islet cell transplantation has recently emerged as one of the most promising therapeutic approaches to improving glycometabolic control in diabetic patients and, in many cases, achieving insulin independence.
Unfortunately, many persistent flaws still prevent islet transplantation from becoming the gold standard treatment for type 1 diabetic patients.
Dr Fiorina and colleagues from Italy reviewed the state of the art of islet transplantation, outcomes, immunosuppressant, and the impact on patients' survival and long-term diabetic complications and eventual alternative options.
The researchers reviewed the many problems in the field, and the challenges to islet survival after transplantation.
The rate of insulin independence 1 year after islet cell transplantation has significantly improved in recent years.
|American Journal of Transplantation|
The team noted that the insulin independence was 60% at 1 year posttransplantation compared with 15% previously.
The team found recent data indicate that restoration of insulin secretion after islet cell transplantation is associated with an improvement in quality of life.
There was a reduction in hypoglycemic episodes, and potentially with a reduction in long-term diabetic complications.
Dr Fiorina’s team concluded, “Once clinical islet transplantation has been successfully established, this treatment could even be offered to diabetic patients long before the onset of diabetic complications.”